RaySearch Laboratories AB (publ) will highlight new advances in particle therapy at PTCOG 64 in Deauville, Normandy, France, June 9–12. At booth #06, visitors can explore the company’s latest software developments, book demonstrations, and learn more about RaySearch’s solutions via the PTCOG event page.
Advancing reirradiation in particle therapy
RaySearch will highlight enhanced support for reirradiation planning and evaluation in the upcoming RayStation release.* Reirradiation means treating a patient again in an area that has already received radiation, which can be challenging due to the dose already delivered to healthy organs. RayStation helps clinics manage this by combining dose from previous and current treatments and making it easier to evaluate the total impact.
The system uses advanced image registration and EQD2 calculations to provide a clearer view of the accumulated dose, taking into account different tissue types and cell recovery over time. Since particle therapy is the most conformal type of radiation, it is particularly well suited for reirradiation treatments which are fundamentally constrained by the cumulative dose to healthy tissues. RayStation can include prior dose directly in the optimization process, helping clinicians balance protecting healthy organs with delivering effective treatment to the target.
Other highlights
RaySearch will have a broad presence at PTCOG 64, and host an annual particle therapy user meeting in conjunction with the conference. PhD students and researchers from RaySearch will also present scientific posters and give presentations. In addition, RaySearch will continue its engagement in UniteRT, reinforcing its commitment to open, vendor-agnostic ecosystems that promote collaboration, choice, and innovation in radiotherapy.
More information about RaySearch’s activities at the event is available here:
RaySearch PTCOG 2026 Event Page
UniteRT Website
“Reirradiation is an area of increasing importance in radiation oncology, where better planning software can make a real difference for clinics and patients,” says Johan Löf, founder and CEO of RaySearch Laboratories. “With the upcoming RayStation release, we are advancing treatment planning in proton therapy and building on our leading position in this growing and strategically important field.”
For more information, please contact:
Matt Miley, Head of Marketing, RaySearch Laboratories AB
Tel: +46 (0) 8 510 530 00
marketing@raysearchlabs.com
Carolina Strömlid, Head of Investor Relations, RaySearch Laboratories AB
Tel: +46 (0) 708 807 173
ir@raysearchlabs.com
About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation® treatment planning system and the oncology information system RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RaySearch’s software has been sold to over 1,200 clinics in 51 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003 (STO: RAY B). More information is available at raysearchlabs.com.
Läs mer om oss på:
LinkedIn
YouTube
RaySearch products are subject to regulatory clearance in some markets.
*This functionality is investigational, not CE-marked or FDA-cleared, and is not available for clinical use.